-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Ocular Therapeutix, Maintains $20 Price Target

Benzinga·12/08/2025 16:19:25
Listen to the news
Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $20 price target.